HRP20170044T1 - Derivati kinolina kao antibakterijska sredstva - Google Patents
Derivati kinolina kao antibakterijska sredstva Download PDFInfo
- Publication number
- HRP20170044T1 HRP20170044T1 HRP20170044TT HRP20170044T HRP20170044T1 HR P20170044 T1 HRP20170044 T1 HR P20170044T1 HR P20170044T T HRP20170044T T HR P20170044TT HR P20170044 T HRP20170044 T HR P20170044T HR P20170044 T1 HRP20170044 T1 HR P20170044T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- compound
- use according
- image
- formula
- Prior art date
Links
- 239000003242 anti bacterial agent Substances 0.000 title claims 7
- 125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 title claims 2
- 229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 27
- 125000000217 alkyl group Chemical group 0.000 claims 19
- 125000005843 halogen group Chemical group 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- 125000003545 alkoxy group Chemical group 0.000 claims 10
- 125000004432 carbon atom Chemical group C* 0.000 claims 10
- -1 cyano, hydroxy Chemical group 0.000 claims 10
- 208000035143 Bacterial infection Diseases 0.000 claims 9
- 208000022362 bacterial infectious disease Diseases 0.000 claims 9
- 150000001204 N-oxides Chemical class 0.000 claims 8
- 229930195734 saturated hydrocarbon Natural products 0.000 claims 8
- 241000894006 Bacteria Species 0.000 claims 6
- 125000004414 alkyl thio group Chemical group 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 241000295644 Staphylococcaceae Species 0.000 claims 5
- 125000001188 haloalkyl group Chemical group 0.000 claims 5
- 150000002431 hydrogen Chemical group 0.000 claims 5
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 5
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 4
- 125000004122 cyclic group Chemical group 0.000 claims 4
- 125000002883 imidazolyl group Chemical group 0.000 claims 4
- 208000015181 infectious disease Diseases 0.000 claims 4
- 125000001624 naphthyl group Chemical group 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 125000003386 piperidinyl group Chemical group 0.000 claims 4
- 125000001544 thienyl group Chemical group 0.000 claims 4
- 241000191967 Staphylococcus aureus Species 0.000 claims 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 3
- 125000006350 alkyl thio alkyl group Chemical group 0.000 claims 3
- 239000003926 antimycobacterial agent Substances 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims 2
- 241000193998 Streptococcus pneumoniae Species 0.000 claims 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 2
- 229960003085 meticillin Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 125000002911 monocyclic heterocycle group Chemical group 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 claims 2
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 claims 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 241000194031 Enterococcus faecium Species 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 229930182555 Penicillin Natural products 0.000 claims 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims 1
- 241000191940 Staphylococcus Species 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002632 imidazolidinyl group Chemical group 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 229940049954 penicillin Drugs 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 1
- 125000004306 triazinyl group Chemical group 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
Claims (34)
1. Uporaba spoja za proizvodnju lijeka za liječenje bakterijske infekcije uzrokovane bakterijama Staphilococci, Enterococci ili Streptococci, navedeni spoj je spoj s formulom (Ia) ili (Ib)
[image]
[image]
njegov N-oksid, njegov tautomerni oblik ili njegov stereokemijski izomerni oblik pri čemu
A- je farmaceutski prihvatljiv ion suprotnog naboja;
R1 je vodik, halo, haloalkil, cijano, hidroksi, Ar, Het, alkil, alkiloksi, alkiltio, alkiloksialkil, alkiltioalkil, Ar-alkil ili di(Ar)alkil ;
p je cijeli broj jednak 1, 2, 3 ili 4 ;
R2 je vodik, hidroksi, merkapto, alkiloksi, alkiloksialkiloksi, alkiltio, mono ili di(alkil)amino ili radikal s formulom
[image]
pri čemu Y je
R3 CH2, O, S, NH ili N-alkil; je alkil, Ar, Ar-alkil, Het ili Het-alkil;
q je cijeli broj jednak nula, 1, 2, 3 ili 4 ;
R4 i R5 svaki neovisno su vodik, alkil ili benzil;
R4 i R5 zajedno i uključujući N za koji su vezani mogu tvoriti radikal koji je odabran iz skupine koja sadrži pirolidinil, 2-pirolinil, 3-pirolinil, pirolil, imidazolidinil, pirazolidinil, 2-imidazolinil, 2-pirazolinil, imidazolil, pirazolil, triazolil, piperidinil, piridinil, piperazinil, piridazinil, pirimidinil, pirazinil, triazinil, morfolinil i tiomorfolinil, svaki od spomenutih prstenova može proizvoljno biti supstituiran sa alkil, halo, haloalkil, hidroksi, alkiloksi, amino, mono- ili dialkilamino, alkiltio, alkiloksialkil, alkiltioalkil, Ar-alkil ili pirimidinil;
R6 je vodik, halo, haloalkil, hidroksi, Ar, alkil, alkiloksi, alkiltio, alkiloksialkil, alkiltioalkil, Ar-alkil ili di(Ar)alkil; ili
dva susjedna R6 radikala mogu se uzeti zajedno da tvore dvovalentni radikal formule
-CH=CH-CH=CH-;
r je cijeli broj jednak 1, 2, 3, 4 ili 5;
R7 je vodik, alkil, Ar ili Het;
R8 je vodik ili alkil;
R9 je okso; ili
R8 i R9 zajedno tvore radikal -CH=CH-N=;
R10 je alkil, alkilkarbonil, Ar, Ar-alkil, Ar-karbonil, Het1-alkil ili Het1-karbonil;
alkil je ravni ili razgranati zasićeni radikal ugljikovodika koji ima od 1 do 6 ugljikovih atoma; ili je ciklički zasićeni radikal ugljikovodika koji ima od 3 do 6 ugljikovih atoma; ili je ciklički zasićeni radikal ugljikovodika koji ima od 3 do 6 ugljikovih atoma vezanih na ravni ili razgranati zasićeni radikal ugljikovodika koji ima od 1 do 6 ugljikovih atoma; pri čemu svaki ugljikov atom može biti proizvoljno supstituiran s hidroksi, alkiloksi ili okso;
Ar je homocikal koji je odabran iz skupine koja sadrži fenil, naftil, acenaftil, tetrahidronaftil, svaki homocikal je proizvoljno supstituiran s 1, 2 ili 3 supstituenata, svaki supstituent je neovisno odabran iz skupine koju čine hidroksi, halo, cijano, nitro, amino, mono- ili dialkilamino, alkil, haloalkil, alkiloksi, haloalkiloksi, karboksil, alkiloksikarbonil, aminokarbonil, morfolinil i mono- ili dialkilaminokarbonil;
Het je monociklički heterocikal odabran iz skupine koju čine N-fenoksipiperidinil, piperidinil, pirolil, pirazolil, imidazolil, furanil, tienil, oksazolil, izoksazolil, tiazolil, izotiazolil, piridinil, pirimidinil, pirazinil i piridazinil; ili biciklički heterocikal odabran iz skupine koju čine kinolinil, kinoksalinil, indolil, benzimidazolil, benzoksazolil, benzizoksazolil, benzotiazolil, benzizotiazolil, benzofuranil, benzotienil, 2,3-dihidrobenzo[1,4]dioksinil i benzo[1,3]dioksolil; svaki monociklički i biciklički heterocikal može proizvoljno biti supstituiran s 1, 2 ili 3 supstituenata, Het1 svaki supstituent je neovisno odabran iz skupine koju čine halo, hidroksi, alkil, alkiloksi, i Ar-karbonil; je monociklički heterocikal odabran od furanila ili tienila; ili biciklički heterocikal odabran od benzofuranila ili benzotienila; svaki monociklički i biciklički heterocikal može proizvoljno biti supstituiran s 1, 2 ili 3 supstituenata, svaki supstituent je neovisno odabran iz skupine koju čine halo, alkil i Ar;
halo je odabran iz skupine koju čine fluor, klor, brom i jod; i
haloalkil je ravni ili razgranati zasićeni radikal ugljikovodika koji ima od 1 do 6 ugljikovih atoma ili ciklički zasićeni radikal ugljikovodika koji ima od 3 do 6 ugljikovih atoma ili ciklički zasićeni radikal ugljikovodika koji ima od 3 do 6 ugljikovih atoma vezanih na ravni ili razgranati zasićeni radikal ugljikovodika koji ima od 1 do 6 ugljikovih atoma; pri čemu su jedan ili više ugljikovih atoma supstituirani s jednim ili više halo atoma.
2. Uporaba prema zahtjevu 1, naznačena time da spoj s formulom (Ia) ili (Ib) je spoj koji ima slijedeću formulu
[image]
[image]
njegov N-oksid, njegov tautomerni oblik ili njegov stereokemijski izomerni oblik.
3. Uporaba prema zahtjevu 1, naznačena time da spoj s formulom (Ia) ili (lb) je spoj koji ima slijedeću formulu
[image]
[image]
njegov N-oksid, njegov tautomerni oblik ili njegov stereokemijski izomerni oblik.
4. Uporaba prema zahtjevu 1, naznačena time da spoj s formulom (Ia) ili (Ib) je spoj koji ima slijedeću formulu
[image]
[image]
njegov N-oksid, njegov tautomerni oblik ili njegov stereokemijski izomerni oblik.
5. Uporaba prema bilo kojem od prethodnih zahtjeva, naznačena time da R1 je halo.
6. Uporaba prema bilo kojem od prethodnih zahtjeva, naznačena time da p je jednak 1.
7. Uporaba prema bilo kojem od prethodnih zahtjeva, naznačena time da R2 je alkiloksi ili alkiltio.
8. Uporaba prema zahtjevu 7, naznačena time da R2 je C1-4alkiloksi.
9. Uporaba prema bilo kojem od prethodnih zahtjeva, naznačena time da R3 je Het, Ar ili Ar-alkil.
10. Uporaba prema zahtjevu 9, naznačena time da R3 je Ar ili Ar-alkil.
11. Uporaba prema zahtjevu 9, naznačena time da R3 je tienil, naftil, fenil, naftilC1-4alkil ili fenilC1-4alkil.
12. Uporaba prema zahtjevu 11, naznačena time da R3 je naftil, fenil ili fenilC1-4alkil.
13. Uporaba prema bilo kojem od prethodnih zahtjeva, naznačena time da R4 i R5 su C1-4alkil ili R4 i R5 zajedno i uključujući N za koji su vezani mogu tvoriti radikal koji je odabran iz niza koji čine imidazolil ili piperidinil.
14. Uporaba prema zahtjevu 13, naznačena time da R4 i R5 su C1-4alkil.
15. Uporaba prema bilo kojem od prethodnih zahtjeva, naznačena time da R6 je vodik ili halo.
16. Uporaba prema bilo kojem od prethodnih zahtjeva, naznačena time da r je jednak 1.
17. Uporaba prema bilo kojem od prethodnih zahtjeva, naznačena time da R7 je vodik.
18. Uporaba prema bilo kojem od prethodnih zahtjeva, naznačena time da R10 je alkil.
19. Uporaba prema zahtjevu 18, naznačena time da R10 je C1-6alkil.
20. Uporaba prema bilo kojem od prethodnih zahtjeva, naznačena time da A- je jodid.
21. Uporaba prema bilo kojem od prethodnih zahtjeva, naznačena time da spoj je spoj prema formuli (Ia).
22. Uporaba spoja s formulom (Ia) prema zahtjevu 1, naznačena time da R1 je halo; p = 1; R2 je alkiloksi ili alkiltio; R3 je naftil, fenil, feniletil ili tienil; q = 1, 2 ili 3; R4 i R5 su C1-4alkil ili R4 i R5 zajedno i uključujući N za koji su vezani mogu tvoriti radikal koji je odabran iz niza koji čine imidazolil ili piperidinil; R6 je vodik ili halo; r je jednak 1; R7 je vodik; R10 je C1-6alkil; A- je jodid.
23. Uporaba prema zahtjevu 1, naznačena time da spoj je odabran od slijedećih spojeva
[image]
njegov N-oksid ili njegov stereokemijski izomerni oblik.
24. Uporaba prema bilo kojem od prethodnih zahtjeva, naznačena time da bakterijska infekcija je infekcija s gram-pozitivnom bakterijom.
25. Spoj s formulom (Ia) ili (Ib)
[image]
[image]
njegov N-oksid, njegov tautomerni oblik ili njegov stereokemijski izomerni oblik naznačen time da R1, p, R2, R3, q, R4, R5, R6, r, R7, R8, R9, R10 i A- su definirani kao u zahtjevu 1;
pod uvjetom da kada R10 je alkil ili benzil, tada R4 i R5 nisu vodik; i pod uvjetom da je spoj različit od
[image]
njegov N-oksid, njegov tautomerni oblik ili njegov stereokemijski izomerni oblik.
26. Spoj prema zahtjevu 25, naznačen time da spoj je odabran od:
[image]
njegov N-oksid ili njegov stereokemijski izomerni oblik.
27. Spoj prema zahtjevu 26, naznačen time da spoj je odabran od :
[image]
ili njegov stereokemijski izomerni oblik, pri čemu stereokemijski izomerni oblik koji je prvi izoliran je označen kao "A" i drugi kao "B".
28. Kombinacija (a) spoja s formulom (Ia) ili (Ib) kako je definirano u bilo kojem od prethodnih zahtjeva, te (b) jednog ili više drugih antibakterijskih sredstava pod uvjetom da su jedno ili više drugih antibakterijskih sredstava različita od antimikobakterijskih sredstava, pri čemu je kombinacija za uporabu za liječenje bakterijske infekcije uzrokovane s bakterijama Staphilococci, Enterococci ili Streptococci.
29. Farmaceutski pripravak, naznačen time da sadrži farmaceutski prihvatljiv nosač, te kao aktivni sastojak, terapeutski učinkovitu količinu (a) spoj s formulom (Ia) ili (Ib) kako je definirano u bilo kojem od zahtjeva 1 do 27, i (b) jedno ili više drugi antibakterijskih sredstava pod uvjetom da su jedno ili više drugih antibakterijskih sredstava različita od antimikobakterijskih sredstava, pri čemu je pripravak za uporabu za liječenje bakterijske infekcije uzrokovane s bakterijama Staphilococci, Enterococci ili Streptococci.
30. Spoj kako je definirano u bilo kojem od zahtjeva 1 do 27, naznačen time da je za uporabu za liječenje bakterijske infekcije uzrokovane s bakterijama Staphilococci, Enterococci ili Streptococci.
31. Proizvod, naznačen time da sadrži (a) spoj s formulom (Ia) ili (lb) kako je definirano u bilo kojem od zahtjeva 1 do 27, i (b) jedno ili više drugi antibakterijskih sredstava pod uvjetom da su jedno ili više drugih antibakterijskih sredstava različita od antimikobakterijskih sredstava, kao kombinirani pripravak za istodobnu, odvojenu ili uzastopnu upotrebu za liječenje bakterijske infekcije uzrokovane sa bakterijama Staphilococci, Enterococci ili Streptococci.
32. Uporaba prema bilo kojem od zahtjeva 1 do 24, kombinacije kako je zatraženo u zahtjevu 28, pripravka kako je zatraženo u zahtjevu 29, spoja kako je zatraženo u zahtjevu 30 ili proizvoda kako je zatraženo u zahtjevu 31, naznačena time da bakterijska infekcija je infekcija sa bakterijom Staphilococcus aureus (MRSA) rezistentnom na meticilin, koagulaza negativnim na meticilin rezistentnim stafilokokom (MRCNS), Streptococcus pneumoniae rezistentne na penicilin ili višestruko rezistentne Enterococcus faecium.
33. Uporaba kombinacije, pripravka, spoja ili proizvoda kako je zatraženo u zahtjevu 32, naznačena time da bakterijska infekcija je infekcija sa bakterijom Staphilococcus aureus ili Streptococcus pneumoniae.
34. Uporaba kombinacije, smjese, spoja ili proizvoda kako je zatraženo u zahtjevu 33, naznačena time da bakterijska infekcija je infekcija sa bakterijom Staphilococcus aureus (MRSA).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05105755 | 2005-06-28 | ||
| PCT/EP2006/063552 WO2007000434A1 (en) | 2005-06-28 | 2006-06-26 | Quinoline derivatives as antibacterial agents |
| EP06763888.2A EP1898909B1 (en) | 2005-06-28 | 2006-06-26 | Quinoline derivatives as antibacterial agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170044T1 true HRP20170044T1 (hr) | 2017-03-10 |
Family
ID=35447198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170044TT HRP20170044T1 (hr) | 2005-06-28 | 2017-01-11 | Derivati kinolina kao antibakterijska sredstva |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US20130030016A1 (hr) |
| EP (1) | EP1898909B1 (hr) |
| JP (1) | JP5193857B2 (hr) |
| KR (1) | KR101329587B1 (hr) |
| CN (1) | CN101252927B (hr) |
| AP (1) | AP2547A (hr) |
| AR (1) | AR054804A1 (hr) |
| AU (1) | AU2006263882B2 (hr) |
| BR (1) | BRPI0613999B8 (hr) |
| CA (1) | CA2612614C (hr) |
| CY (1) | CY1119402T1 (hr) |
| DK (1) | DK1898909T3 (hr) |
| EA (1) | EA014431B1 (hr) |
| ES (1) | ES2610472T3 (hr) |
| HK (1) | HK1120732A1 (hr) |
| HR (1) | HRP20170044T1 (hr) |
| HU (1) | HUE030264T2 (hr) |
| IL (1) | IL188395A (hr) |
| JO (1) | JO3322B1 (hr) |
| LT (1) | LT1898909T (hr) |
| MX (1) | MX2008000079A (hr) |
| MY (1) | MY173664A (hr) |
| NO (1) | NO341285B1 (hr) |
| NZ (1) | NZ564340A (hr) |
| PL (1) | PL1898909T3 (hr) |
| PT (1) | PT1898909T (hr) |
| RS (1) | RS55601B1 (hr) |
| SG (1) | SG166798A1 (hr) |
| TW (1) | TWI413520B (hr) |
| UA (1) | UA88701C2 (hr) |
| WO (1) | WO2007000434A1 (hr) |
| ZA (1) | ZA200711148B (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO2752B1 (en) | 2005-06-28 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | Quinoline derivatives acting as antibacterial agents |
| JO2683B1 (en) * | 2006-12-06 | 2013-03-03 | جانسين فارماسوتيكا ان. في | Quinoline antibacterial derivatives |
| JO2970B1 (en) | 2006-12-06 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Quinoline antibacterial derivatives |
| JP5397881B2 (ja) * | 2008-09-04 | 2014-01-22 | 昇一 城武 | グラム陽性細菌用抗菌剤及び抗菌活性増強剤 |
| ES2607879T3 (es) | 2012-04-27 | 2017-04-04 | Janssen Pharmaceutica N.V. | Derivados de quinolina antibacterianos |
| JP6153604B2 (ja) | 2012-04-27 | 2017-06-28 | ヤンセン ファーマシューティカ エヌ．ベー． | 抗菌性キノリン誘導体 |
| JP2020536966A (ja) * | 2017-10-13 | 2020-12-17 | ザ ユニバーシティー オブ クイーンズランド | 亜鉛イオノフォアおよびその使用 |
| CN110606825A (zh) * | 2019-10-30 | 2019-12-24 | 成都海杰亚医药科技有限公司 | 一种制备吡啶-2-硫醇的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6103905A (en) * | 1997-06-19 | 2000-08-15 | Sepracor, Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
| DE60332023D1 (de) * | 2002-07-25 | 2010-05-20 | Janssen Pharmaceutica Nv | Chinolinderivate und deren verwendung als mycobakterielle inhibitoren |
| PT1753427E (pt) * | 2004-05-28 | 2008-07-04 | Janssen Pharmaceutica Nv | Utilização de derivados quinolina substituídos para o tratamento de doenças micobacterianas resistentes a fármacos |
| EE05394B1 (et) * | 2004-12-24 | 2011-04-15 | Janssen Pharmaceutica N.V. | Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis |
| EE05697B1 (et) * | 2005-06-08 | 2014-02-17 | Janssen Pharmaceutica N.V. | Kinoliini derivaadid kui antibakteriaalsed toimeained |
-
2006
- 2006-06-26 JP JP2008518809A patent/JP5193857B2/ja active Active
- 2006-06-26 SG SG201007976-2A patent/SG166798A1/en unknown
- 2006-06-26 UA UAA200714928A patent/UA88701C2/ru unknown
- 2006-06-26 EP EP06763888.2A patent/EP1898909B1/en active Active
- 2006-06-26 HU HUE06763888A patent/HUE030264T2/en unknown
- 2006-06-26 MX MX2008000079A patent/MX2008000079A/es active IP Right Grant
- 2006-06-26 BR BRPI0613999A patent/BRPI0613999B8/pt not_active IP Right Cessation
- 2006-06-26 CA CA2612614A patent/CA2612614C/en active Active
- 2006-06-26 WO PCT/EP2006/063552 patent/WO2007000434A1/en active Application Filing
- 2006-06-26 AU AU2006263882A patent/AU2006263882B2/en active Active
- 2006-06-26 NZ NZ564340A patent/NZ564340A/en unknown
- 2006-06-26 DK DK06763888.2T patent/DK1898909T3/en active
- 2006-06-26 PT PT67638882T patent/PT1898909T/pt unknown
- 2006-06-26 CN CN200680031302.9A patent/CN101252927B/zh active Active
- 2006-06-26 MY MYPI20063021A patent/MY173664A/en unknown
- 2006-06-26 LT LTEP06763888.2T patent/LT1898909T/lt unknown
- 2006-06-26 KR KR1020087002246A patent/KR101329587B1/ko active IP Right Grant
- 2006-06-26 EA EA200800151A patent/EA014431B1/ru unknown
- 2006-06-26 PL PL06763888T patent/PL1898909T3/pl unknown
- 2006-06-26 RS RS20170045A patent/RS55601B1/sr unknown
- 2006-06-26 ES ES06763888.2T patent/ES2610472T3/es active Active
- 2006-06-26 AP AP2008004298A patent/AP2547A/xx active
- 2006-06-27 AR ARP060102758A patent/AR054804A1/es unknown
- 2006-06-27 TW TW095123049A patent/TWI413520B/zh active
- 2006-06-29 JO JOP/2006/0183A patent/JO3322B1/ar active
-
2007
- 2007-12-20 ZA ZA2007/11148A patent/ZA200711148B/en unknown
- 2007-12-25 IL IL188395A patent/IL188395A/en active IP Right Grant
-
2008
- 2008-01-28 NO NO20080499A patent/NO341285B1/no not_active IP Right Cessation
- 2008-11-17 HK HK08112566.1A patent/HK1120732A1/xx unknown
-
2012
- 2012-08-07 US US13/568,569 patent/US20130030016A1/en not_active Abandoned
-
2017
- 2017-01-11 HR HRP20170044TT patent/HRP20170044T1/hr unknown
- 2017-01-18 CY CY20171100071T patent/CY1119402T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170044T1 (hr) | Derivati kinolina kao antibakterijska sredstva | |
| HRP20131116T1 (hr) | Derivati kinolina kao antibakterijska sredstva | |
| HRP20140206T1 (hr) | Derivati kinolina kao antibakterijska sredstva | |
| JP2009503024A5 (hr) | ||
| HRP20161704T1 (hr) | Derivati kinolina kao antibakterijska sredstva | |
| HRP20160585T1 (hr) | Antibakterijski derivati kinolina | |
| JP2009503025A5 (hr) | ||
| HRP20110392T1 (hr) | Derivati kinolina za liječenje latentne tuberkuloze | |
| HRP20120910T1 (hr) | Derivati kinolina kao antibakterijska sredstva | |
| CA2566544A1 (en) | Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases | |
| HRP20120912T1 (hr) | Derivati kinolina kao antibakterijska sredstva | |
| MX2021015605A (es) | Compuestos 2,3-dihidroquinazolin como inhibidores nav1.8. | |
| NZ702796A (en) | Immunogenic anti-inflammatory compositions | |
| HRP20210484T1 (hr) | Antimikrobna sredstva koja se temelje na imidazolu | |
| CA2493225A1 (en) | Quinoline derivatives and their use as mycobacterial inhibitors | |
| HRP20100696T1 (hr) | Hiv inhibirajuci 5-(hidroksimetilen i aminometilen) supstituirani pirimidini | |
| JP2008546824A5 (hr) | ||
| MY159560A (en) | Quinoline derivatives as antibacterial agents | |
| HRP20100428T1 (hr) | Antibakterijski derivati kvinolina | |
| JP2009503021A5 (hr) | ||
| HRP20221356T1 (hr) | Nova alkilirajuća sredstva | |
| HRP20110540T1 (hr) | Antibakterijski derivati kinolina | |
| JP2010511667A5 (hr) | ||
| JP2008543964A5 (hr) | ||
| JP2008546825A5 (hr) |